{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T05:45:19Z","timestamp":1713505519978},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,25]]},"DOI":"10.7759\/cureus.30653","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T08:06:54Z","timestamp":1666685214000},"source":"Crossref","is-referenced-by-count":1,"title":["A 98-Year-Old Male With Paroxysmal Atrial Fibrillation Treated for COVID-19 at Home"],"prefix":"10.7759","author":[{"given":"Fabrizia","family":"Farolfi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Cavazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Mangiagalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Cavanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Gestione domiciliare dei pazienti con infezione da SARS-CoV-2. (2020). Accessed. September 29, 2022: https:\/\/www.trovanorme.salute.gov.it\/norme\/renderNormsanPdf?anno=2020&amp;codLeg=77456&amp;parte=1%20&amp;serie=null."},{"key":"ref2","unstructured":"Farmaci utilizzabili per il trattamento della malattia COVID-19. (2022). Accessed. September 29, 2022: https:\/\/www.aifa.gov.it\/aggiornamento-sui-farmaci-utilizzabili-per-il-trattamento-della-malattia-covid19."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.935379","article-title":"Retrospective study of outcomes and hospitalization rates of patients in Italy with a confirmed diagnosis of early COVID-19 and treated at home within 3 days or after 3 days of symptom onset with prescribed and non-prescribed treatments between November 2020 and August 2021","volume":"27","author":"Fazio S","year":"2021","unstructured":"Fazio S, Bellavite P, Zanolin E, McCullough PA, Pandolfi S, Affuso F. Retrospective study of outcomes and hospitalization rates of patients in Italy with a confirmed diagnosis of early COVID-19 and treated at home within 3 days or after 3 days of symptom onset with prescribed and non-prescribed treatments between November 2020 and August 2021. Med Sci Monit. 2021, 27:e935379. 10.12659\/MSM.935379","journal-title":"Med Sci Monit"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100941","article-title":"A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: a retrospective observational matched-cohort study","volume":"37","author":"Suter F","year":"2021","unstructured":"Suter F, Consolaro E, Pedroni S, et al.. A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: a retrospective observational matched-cohort study. EClinicalMedicine. 2021, 37:100941. 10.1016\/j.eclinm.2021.100941","journal-title":"EClinicalMedicine"},{"key":"ref5","doi-asserted-by":"crossref","DOI":"10.34297\/AJBSR.2022.16.002197","article-title":"COVID-19 early treatment with non-steroidal anti-inflammatory drugs reduces hospitalizations and symptom duration","volume":"16","author":"Fazio S","year":"2022","unstructured":"Fazio S, Grimaldi S, D\u2019Emilio M, Mangiagalli A, Affuso F. COVID-19 early treatment with non-steroidal anti-inflammatory drugs reduces hospitalizations and symptom duration. Am J Biomed Sci Res. 2022, 16:99-101.","journal-title":"Am J Biomed Sci Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm.2020.04.264","article-title":"Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19)","volume":"21","author":"McCullough PA","year":"2020","unstructured":"McCullough PA, Alexander PE, Armstrong R, et al.. Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19). Rev Cardiovasc Med. 2020, 21:517-30. 10.31083\/j.rcm.2020.04.264","journal-title":"Rev Cardiovasc Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.255.61","article-title":"COVID-19 outbreak in Italy: report on the first 124 consecutive patients treated at home","volume":"255","author":"Cavanna L","year":"2021","unstructured":"Cavanna L, Cremona G, Citterio C, et al.. COVID-19 outbreak in Italy: report on the first 124 consecutive patients treated at home. Tohoku J Exp Med. 2021, 255:61-9. 10.1620\/tjem.255.61","journal-title":"Tohoku J Exp Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.26502\/fjppr.055","article-title":"The problem of home therapy during COVID-19 pandemic in Italy: government guidelines versus freedom of cure?","volume":"6","author":"Fazio S","year":"2022","unstructured":"Fazio S, Cosentino M, Marino F, Pandolfi S, Zanolin E, Bellavite P. The problem of home therapy during COVID-19 pandemic in Italy: government guidelines versus freedom of cure?. J Pharm Pharmacol Res. 2022, 6:100-14. 10.26502\/fjppr.055","journal-title":"J Pharm Pharmacol Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00433-9","article-title":"Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents","author":"Perico N","year":"2022","unstructured":"Perico N, Cortinovis M, Suter F, Remuzzi G. Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents. Lancet Infect Dis. 2022, 10.1016\/S1473-3099(22)00433-9","journal-title":"Lancet Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-10370-1","article-title":"An open label randomized clinical trial of indomethacin for mild and moderate hospitalised Covid-19 patients","volume":"12","author":"Ravichandran R","year":"2022","unstructured":"Ravichandran R, Mohan SK, Sukumaran SK, et al.. An open label randomized clinical trial of indomethacin for mild and moderate hospitalised Covid-19 patients. Sci Rep. 2022, 12:6413. 10.1038\/s41598-022-10370-1","journal-title":"Sci Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2022.02.006","article-title":"Thromboprophylaxis in patients with COVID-19: a brief update to the chest guideline and expert panel report","volume":"162","author":"Moores LK","year":"2022","unstructured":"Moores LK, Tritschler T, Brosnahan S, et al.. Thromboprophylaxis in patients with COVID-19: a brief update to the chest guideline and expert panel report. Chest. 2022, 162:213-25. 10.1016\/j.chest.2022.02.006","journal-title":"Chest"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2147\/JEP.S330776","article-title":"Aspirin as an adjunctive pharmacologic therapy option for COVID-19: anti-inflammatory, antithrombotic, and antiviral effects all in one agent","volume":"13","author":"Tantry US","year":"2021","unstructured":"Tantry US, Schror K, Navarese EP, Jeong YH, Kubica J, Bliden KP, Gurbel PA. Aspirin as an adjunctive pharmacologic therapy option for COVID-19: anti-inflammatory, antithrombotic, and antiviral effects all in one agent. J Exp Pharmacol. 2021, 13:957-70. 10.2147\/JEP.S330776","journal-title":"J Exp Pharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.112965","article-title":"Changes in the immune response against SARS-CoV-2 in individuals with severe COVID-19 treated with high dose of vitamin D","volume":"150","author":"Torres M","year":"2022","unstructured":"Torres M, Casado G, Vig\u00f3n L, et al.. Changes in the immune response against SARS-CoV-2 in individuals with severe COVID-19 treated with high dose of vitamin D. Biomed Pharmacother. 2022, 150:112965. 10.1016\/j.biopha.2022.112965","journal-title":"Biomed Pharmacother"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-021-01614-4","article-title":"Vitamin D supplementation and clinical outcomes in COVID-19: a systematic review and meta-analysis","volume":"45","author":"Pal R","year":"2022","unstructured":"Pal R, Banerjee M, Bhadada SK, Shetty AJ, Singh B, Vyas A. Vitamin D supplementation and clinical outcomes in COVID-19: a systematic review and meta-analysis. J Endocrinol Invest. 2022, 45:53-68. 10.1007\/s40618-021-01614-4","journal-title":"J Endocrinol Invest"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112378","article-title":"Vitamin D levels in COVID-19 outpatients from western Mexico: clinical correlation and effect of its supplementation","volume":"10","author":"S\u00e1nchez-Zuno GA","year":"2021","unstructured":"S\u00e1nchez-Zuno GA, Gonz\u00e1lez-Estevez G, Matuz-Flores MG, et al.. Vitamin D levels in COVID-19 outpatients from western Mexico: clinical correlation and effect of its supplementation. J Clin Med. 2021, 10:2378. 10.3390\/jcm10112378","journal-title":"J Clin Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.936292","article-title":"A review of the potential roles of antioxidant and anti-inflammatory pharmacological approaches for the management of mild-to-moderate symptomatic COVID-19","volume":"28","author":"Fazio S","year":"2022","unstructured":"Fazio S, Affuso F, Bellavite P. A review of the potential roles of antioxidant and anti-inflammatory pharmacological approaches for the management of mild-to-moderate symptomatic COVID-19. Med Sci Monit. 2022, 28:e936292. 10.12659\/MSM.936292","journal-title":"Med Sci Monit"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S318720","article-title":"Possible therapeutic effects of adjuvant quercetin supplementation against early-stage COVID-19 infection: a prospective, randomized, controlled, and open-label study","volume":"14","author":"Di Pierro F","year":"2021","unstructured":"Di Pierro F, Derosa G, Maffioli P, et al.. Possible therapeutic effects of adjuvant quercetin supplementation against early-stage COVID-19 infection: a prospective, randomized, controlled, and open-label study. Int J Gen Med. 2021, 14:2359-66. 10.2147\/IJGM.S318720","journal-title":"Int J Gen Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S318949","article-title":"Potential clinical benefits of quercetin in the early stage of COVID-19: results of a second, pilot, randomized, controlled and open-label clinical trial","volume":"14","author":"Di Pierro F","year":"2021","unstructured":"Di Pierro F, Iqtadar S, Khan A, et al.. Potential clinical benefits of quercetin in the early stage of COVID-19: results of a second, pilot, randomized, controlled and open-label clinical trial. Int J Gen Med. 2021, 14:2807-16. 10.2147\/IJGM.S318949","journal-title":"Int J Gen Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.674681","article-title":"Vitamin C may increase the recovery rate of outpatient cases of SARS-CoV-2 infection by 70%: reanalysis of the COVID A to Z randomized clinical trial","volume":"12","author":"Hemil\u00e4 H","year":"2021","unstructured":"Hemil\u00e4 H, Carr A, Chalker E. Vitamin C may increase the recovery rate of outpatient cases of SARS-CoV-2 infection by 70%: reanalysis of the COVID A to Z randomized clinical trial. Front Immunol. 2021, 12:674681. 10.3389\/fimmu.2021.674681","journal-title":"Front Immunol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-057024","article-title":"Dietary supplements to reduce symptom severity and duration in people with SARS-CoV-2: study protocol for a randomised, double-blind, placebo controlled clinical trial","volume":"12","author":"Legacy M","year":"2022","unstructured":"Legacy M, Seely D, Conte E, et al.. Dietary supplements to reduce symptom severity and duration in people with SARS-CoV-2: study protocol for a randomised, double-blind, placebo controlled clinical trial. BMJ Open. 2022, 12:e057024. 10.1136\/bmjopen-2021-057024","journal-title":"BMJ Open"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/119412-a-98-year-old-male-with-paroxysmal-atrial-fibrillation-treated-for-covid-19-at-home","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:49:58Z","timestamp":1707508198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/119412-a-98-year-old-male-with-paroxysmal-atrial-fibrillation-treated-for-covid-19-at-home"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,25]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.30653","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,25]]}}}